PURPOSE: Although previous studies have demonstrated an inverse relationship between folate intake and colorectal cancer risk, a recent trial suggests that supplemental folic acid may accelerate tumorigenesis among patients with a history of colorectal adenoma. Therefore, high priority has been given to research investigating the influence of folate on cancer progression in patients with colorectal cancer. PATIENTS AND METHODS: To investigate whether prediagnostic levels of plasma folate are associated with colorectal cancer-specific and overall mortality, we performed a prospective, nested observational study within two large US cohorts: the Nurses' Health Study and Health Professionals Follow-Up Study. We measured folate levels among 301 participants who developed colorectal cancer 2 or more years after their plasma was collected and compared participants using Cox proportional hazards models by quintile of plasma folate. RESULTS: Higher levels of plasma folate were not associated with an increased risk of colorectal cancer-specific or overall mortality. Compared with participants in the lowest quintile of plasma folate, those in the highest quintile experienced a multivariable-adjusted hazard ratio for colorectal cancer-specific mortality of 0.42 (95% CI, 0.20 0.88) and overall mortality of 0.46 (95% CI, 0.24 0.88). When the analysis was limited to participants whose plasma was collected within 5 years of cancer diagnosis, no detrimental effect of high plasma folate was noted. In subgroup analyses, no subgroup demonstrated worse survival among participants with higher plasma folate levels. CONCLUSION: In two large prospective cohorts, higher prediagnostic levels of plasma folate were not associated with an increased risk of colorectal cancer-specific or overall mortality.
PURPOSE: Although previous studies have demonstrated an inverse relationship between folate intake and colorectal cancer risk, a recent trial suggests that supplemental folic acid may accelerate tumorigenesis among patients with a history of colorectal adenoma. Therefore, high priority has been given to research investigating the influence of folate on cancer progression in patients with colorectal cancer. PATIENTS AND METHODS: To investigate whether prediagnostic levels of plasma folate are associated with colorectal cancer-specific and overall mortality, we performed a prospective, nested observational study within two large US cohorts: the Nurses' Health Study and Health Professionals Follow-Up Study. We measured folate levels among 301 participants who developed colorectal cancer 2 or more years after their plasma was collected and compared participants using Cox proportional hazards models by quintile of plasma folate. RESULTS: Higher levels of plasma folate were not associated with an increased risk of colorectal cancer-specific or overall mortality. Compared with participants in the lowest quintile of plasma folate, those in the highest quintile experienced a multivariable-adjusted hazard ratio for colorectal cancer-specific mortality of 0.42 (95% CI, 0.20 0.88) and overall mortality of 0.46 (95% CI, 0.24 0.88). When the analysis was limited to participants whose plasma was collected within 5 years of cancer diagnosis, no detrimental effect of high plasma folate was noted. In subgroup analyses, no subgroup demonstrated worse survival among participants with higher plasma folate levels. CONCLUSION: In two large prospective cohorts, higher prediagnostic levels of plasma folate were not associated with an increased risk of colorectal cancer-specific or overall mortality.
Authors: Bernard F Cole; John A Baron; Robert S Sandler; Robert W Haile; Dennis J Ahnen; Robert S Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard I Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Douglas J Robertson; Gerald J Beck; John H Bond; Tim Byers; Jack S Mandel; Leila A Mott; Loretta H Pearson; Elizabeth L Barry; Judy R Rees; Norman Marcon; Fred Saibil; Per Magne Ueland; E Robert Greenberg Journal: JAMA Date: 2007-06-06 Impact factor: 56.272
Authors: P Thirion; S Michiels; J P Pignon; M Buyse; A C Braud; R W Carlson; M O'Connell; P Sargent; P Piedbois Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Cynthia K Colapinto; Deborah L O'Connor; Margaret Sampson; Brock Williams; Mark S Tremblay Journal: J Public Health (Oxf) Date: 2015-07-09 Impact factor: 2.341
Authors: Jane C Figueiredo; Leila A Mott; Edward Giovannucci; Kana Wu; Bernard Cole; Matthew J Grainge; Richard F Logan; John A Baron Journal: Int J Cancer Date: 2011-04-01 Impact factor: 7.396
Authors: Johanna C Bendell; Suzanne F Jones; Lowell Hart; David R Spigel; Cassie M Lane; Chris Earwood; Jeffrey R Infante; John Barton; Howard A Burris Journal: Invest New Drugs Date: 2014-10-22 Impact factor: 3.850
Authors: Paul Lochhead; Reiko Nishihara; Zhi Rong Qian; Kosuke Mima; Yin Cao; Yasutaka Sukawa; Sun A Kim; Kentaro Inamura; Xuehong Zhang; Kana Wu; Edward Giovannucci; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino Journal: Am J Clin Nutr Date: 2015-09-30 Impact factor: 7.045
Authors: Katia Lofano; Mariabeatrice Principi; Maria Principia Scavo; Maria Pricci; Enzo Ierardi; Alfredo Di Leo Journal: J Gastrointest Cancer Date: 2013-03
Authors: Youjin Je; Jung Eun Lee; Jing Ma; Xuehong Zhang; Eunyoung Cho; Bernard Rosner; Jacob Selhub; Charles S Fuchs; Jeffrey Meyerhardt; Edward Giovannucci Journal: Cancer Causes Control Date: 2013-01-23 Impact factor: 2.506